Drug Profile
Research programme: irinotecan nanoparticles - Valerio Therapeutics
Alternative Names: BA-018; Irinotecan-TransdrugLatest Information Update: 08 Sep 2023
Price :
$50
*
At a glance
- Originator BioAlliance Pharma
- Developer Valerio Therapeutics
- Class Alkaloids; Antineoplastics; Camptothecins; Carboxylic acids; Esters; Indolizines; Piperidines; Pyrans; Quinolines; Small molecules
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Colorectal cancer
Most Recent Events
- 03 Sep 2014 Discontinued - Preclinical for Colorectal cancer in France (PO)
- 01 Aug 2014 TopoTarget has merged with BioAlliance Pharma to form Onxeo SA
- 03 Mar 2009 Preclinical trials in Colorectal cancer in France (PO)